Korea’s CJ Looking To P-CAB, Biosimilars To Double Revenues

CJ HealthCare, the pharma affiliate of South Korea's CJ Group, is aiming to more than double its annual revenues to KRW1 trillion ($910 million) by 2020 by developing new drugs and biosimilars.